Alitretinoin clinical trials
Also written 9-cis-retinoic acid.
How each study uses Alitretinoin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 2 Feb 1999 · PANRETIN · NDA 020886 (FDA, Drugs@FDA)
- European Union
- 11 Oct 2000 · Panretin · EMEA/H/C/000279 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 7
Basilea Pharmaceutica (4) · Stiefel, a GSK Company (2) · Anderson Clinical Research (2) · University Medical Center Groningen (2) · University Hospital, Gentofte, Copenhagen (1) · National Cancer Institute (NCI) (1) · University Hospital Muenster (1) · Technische Universität Dresden (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Alitretinoin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand DermatitisCompletedPhase 3Basilea PharmaceuticaNCT00124436Written as alitretinoinHow we know
- Alitretinoin in the Treatment of Chronic Hand EczemaCompletedPhase 3Basilea PharmaceuticaNCT00519675Written as alitretinoinHow we know
- Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand DermatitisCompletedPhase 3Basilea PharmaceuticaNCT00309621Written as alitretinoinHow we know
- Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand DermatitisCompletedPhase 3Basilea PharmaceuticaNCT00124475Written as alitretinoinHow we know
- Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand EczemaCompletedPhase 3Stiefel, a GSK CompanyNCT00817063Written as alitretinoinHow we know
- Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand EczemaStatus unknownPhase 3University Medical Center GroningenNCT03026946Written as AlitretinoinHow we know
- Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand EczemaStatus unknownPhase 3University Medical Center GroningenNCT03026907Written as AlitretinoinHow we know
- Efficacy of Alitretinoin Treatment in Patients With Pustular Form of PsoriasisCompletedPhase 2Stiefel, a GSK CompanyNCT01245140Written as alitretinoinHow we know
- Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus ErythematosusTerminatedPhase 2University Hospital MuensterNCT01407679Written as AlitretinoinHow we know
- Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.TerminatedPhase 4Technische Universität DresdenNCT01231854Written as AlitretinoinHow we know
- Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic DiseaseCompletedPhase 1/2University Hospital, Gentofte, CopenhagenNCT01261923Written as AlitretinoinHow we know
- Lichen Planus Mucosae at USZ, Efficacy of Oral AlitretinoinStatus unknownPhase 2University of ZurichNCT01538732Written as alitretinoinHow we know
- A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer PatientsCompletedPhase 1National Cancer Institute (NCI)NCT00001504Written as 9-cis-Retinoic AcidHow we know
- A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's SarcomaCompletedNot applicableAnderson Clinical ResearchNCT00002439Written as AlitretinoinHow we know
- A Study of ALRT1057 in Patients With AIDS-Related Kaposi's SarcomaCompletedPhase 2Anderson Clinical ResearchNCT00002188Written as AlitretinoinHow we know
Given beside what is tested · 1 — Alitretinoin is usual care or a partner of the new treatment
- Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.Status unknownPhase 3Mahmoud Ramadan mohamed ElkazzazNCT05016349Written as 9 cis retinoic acidHow we know
As the comparator · 1 — what is tested is compared with Alitretinoin
Codes
What other systems call Alitretinoin · ClinicalTrials.gg INT006752
- MeSH (NLM) D000077556AlitretinoinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1UA8E65KDZALITRETINOINConfirmed FDA, NLM, Wikidata
- RxNorm 81864Confirmed FDA, Wikidata
- Wikidata Q3611854alitretinoinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1574AlitretinoinOne source FDA
- DrugBank DB00523One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077556 | Alitretinoin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1UA8E65KDZ | ALITRETINOIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 81864 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3611854 | alitretinoin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1574 | Alitretinoin | One source FDA |
| DrugBank | DB00523 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.